

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

CD133/1 (AC133)-PE, human

RRID:AB_2660882

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-098-826, RRID:AB_2660882

Antibody Information

URL: http://antibodyregistry.org/AB_2660882

Proper Citation: Miltenyi Biotec Cat# 130-098-826, RRID:AB_2660882

Target Antigen: CD133/1 (AC133)

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 6-2018; Target Distribution brain, endothelial cells, epithelial cells, heart, hematopoietic stem cells, kidney, liver, lung, pancreas, placenta, ES and iPS cells, red blood cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-670. (RRID:AB_2726212).

Antibody Name: CD133/1 (AC133)-PE, human

Description: This monoclonal targets CD133/1 (AC133)

Target Organism: human

Clone ID: AC133

Antibody ID: AB_2660882

Vendor: Miltenyi Biotec

Catalog Number: 130-098-826

Record Creation Time: 20250820T063236+0000

Record Last Update: 20250821T002338+0000

Ratings and Alerts

No rating or validation information has been found for CD133/1 (AC133)-PE, human.

Warning: Discontinued: 2021

Discontinued: 6-2018; Target Distribution brain, endothelial cells, epithelial cells, heart, hematopoietic stem cells, kidney, liver, lung, pancreas, placenta, ES and iPS cells, red blood cells; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-670. (RRID:AB_2726212).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Qiu Z, et al. (2022) Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells. Cancer discovery, 12(2), 502.

Essex A, et al. (2019) Replication Study: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. eLife, 8.